All posts

Ianthus Capital is a double, Beacon Securities says

iAnthus CEO Hadley Ford

In a coverage resumption on Thursday, Beacon Securities analyst Russell Stanley rates US cannabis company Ianthus Capital Holdings (Ianthus Capital Stock Quote, Chart CSE:IAN) a “Buy” with a 12-month target price of C$12.50, representing a projected return of 98 per cent.

Last week, Ianthus Capital —which owns and operates licensed cannabis cultivation, processing and dispensary facilities in the United States— announced an agreement to acquire MPX Bioceutical Corporation (CSE:MPX), a medical marijuana operation in Arizona, in an all-stock transaction.

Stanley calls the deal, expected to be completed in January, 2019, “the most significant near-term catalyst” for IAN, making it one of the largest multi-state operators in the US. The acquisition means IAN will gain a $50 million + revenue business in Arizona as well as growth assets in Nevada and Maryland. (All figures in US dollars unless noted otherwise.) The combined company will have an aggregate cultivation and production footprint of 212,100 sq. ft., potential expansion to 553,000 sq. ft., 15 dispensaries and licenses to grow that number to 56, says Stanley.

Ianthus Capital stock trading at a discount

“Cannabis companies with operations in the United States now trade an average multiple discount of 72 per cent relative to Canadian operators (9.9x vs. 35.1x EV/C2020E EBITDA, based on consensus expectations),” says the analyst. “We view this discount as unsustainably high, and expect multiples to converge as investors will eventually realize that US operating companies generally offer investors more established business models with far broader product suites and greater participation throughout the value chain (cultivation, manufacturing/production and retail).”

Stanley predicts Ianthus will produce revenue and adjusted EBITDA in 2019 of $201 million and $37 million, respectively, and revenue and adjusted EBITDA in 2020 of $336 million and $116 million, respectively.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: ian
Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

Is Peloton Stock a Buy? (May, 2024)

Following news of a restructuring, Roth MKM analyst George Kelly has chopped his price target on Peloton (Peloton Stock Quote,… [Read More]

2 days ago

Is Ascend Wellness stock a buy?

Ahead of the company's first quarter results, Beacon analyst Russell Stanley thinks Ascend Wellness (Ascend Wellness Stock Quote, Chart, News,… [Read More]

2 days ago

Paradigm chops price target on Snipp Interactive

Following the company's fourth quarter results, Paradigm Capital analyst Daniel Rosenberg has cut his price target on Snipp Interactive (Snipp… [Read More]

2 days ago

It’s time to buy cannabis stocks, this analyst says

A major development came down the pipe this week at the U.S. Drug Enforcement Agency has reportedly decided to reschedule… [Read More]

3 days ago

Is Generac stock a buy?

Following the company's first quarter results, Roth MKM analyst Chip Moore remains neutral on Generac Holdings (Generac Holdings Stock Quote,… [Read More]

3 days ago

Bombardier is a buy, Desjardins says (May, 2024)

The stock has climbed slowly but surely since last October. But is there still money to be made on Bombardier?… [Read More]

3 days ago